Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mydayis
Marketing
Shire launches ADHD med Mydayis as it weighs a neuroscience exit
Shire has rolled out Mydayis, its new Adderall formulation, at a list price of $271 per month. The aim? Hitting $500 million in sales.
Eric Sagonowsky
Aug 28, 2017 10:15am
Shire hints at ADHD spinoff, but could someone buy the neuro group?
Aug 3, 2017 12:00pm
Shire scores FDA nod for Mydayis, its latest Adderall iteration
Jun 21, 2017 10:32am
